Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma Subjects

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

160

Participants

Timeline

Start Date

May 11, 2025

Primary Completion Date

May 26, 2026

Study Completion Date

May 26, 2027

Conditions

Bronchial Asthma

Interventions

DRUG

MG-ZG122 Humanized Monoclonal Antibody Injection

OTHER

Placebo

MG-ZG122 Humanized Monoclonal Antibody Injection Placebo

Trial Locations (1)

China-Japan Friendship Hospital, Beijing, China, Beijing

All Listed Sponsors

lead

Shanghai Mabgeek Biotech.Co.Ltd

OTHER_GOV